Constipation on Wegovy (semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations
How common is constipation on Wegovy? Trial-level incidence data, severity breakdown, risk factors, typical timeline, and when to call your prescriber.
12 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 12 of 12 clinical reviews.
How common is constipation on Wegovy? Trial-level incidence data, severity breakdown, risk factors, typical timeline, and when to call your prescriber.
A phase-by-phase breakdown of when constipation starts, peaks, and typically resolves during Wegovy dose escalation, backed by STEP trial data and GI motility research.
Specific dietary changes, hydration targets, meal-timing strategies, and evidence-backed supplements that reduce constipation caused by Wegovy (semaglutide 2.4 mg).
Evidence-based dietary strategies to relieve constipation caused by Wegovy (semaglutide 2.4 mg), including fiber targets, hydration goals, and foods to prioritize or avoid, with notes on where the evidence is strong versus where it is general nutrition extrapolation.
A clinically specific, step-by-step protocol for assessing and treating constipation caused by Wegovy (semaglutide 2.4 mg), including first-line interventions, escalation criteria, and discontinuation triggers.
OTC and prescription options for treating constipation caused by Wegovy (semaglutide 2.4 mg), including first-line osmotic laxatives, second-line prokinetics, drug interactions to avoid, and when to escalate care.
Wegovy causes constipation in up to 24% of users. Learn why semaglutide slows gut transit, how to manage it, and which GLP-1 alternatives carry a lower constipation burden.
A clinical guide to grading constipation severity on Wegovy (semaglutide 2.4 mg), with evidence-based management strategies, mechanistic explanations, and when to contact your prescriber.
Wegovy slows gut transit and causes constipation in roughly 24% of users. This evidence-based guide covers why it happens, how long it lasts, and which supplements have the strongest clinical support for relief.
Persistent constipation is one of the most commonly reported gastrointestinal side effects of Wegovy (semaglutide 2.4 mg). Here is why it happens, how to tell ordinary adjustment from a problem that needs treatment, and a stepwise, evidence-based approach to managing it.
Clinical criteria for discontinuing Wegovy due to constipation, including severity thresholds, lab red flags, quality-of-life impact, and alternative GLP-1 options.
Clinical explanation of how semaglutide slows gut transit time across the entire GI tract, causing constipation in Wegovy patients, with actionable management steps.

LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.